Home » Stocks » PACB

Pacific Biosciences of California, Inc. (PACB)

Stock Price: $14.54 USD 0.13 (0.90%)
Updated November 25, 4:00 PM EST - Market closed
After-hours: $14.35 -0.19 (-1.31%) Nov 25, 7:55 PM

Stock Price Chart

Key Info

Market Cap 2.72B
Revenue (ttm) 79.69M
Net Income (ttm) -45.62M
Shares Out 187.22M
EPS (ttm) -0.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 25
Last Price $14.54
Previous Close $14.41
Change ($) 0.13
Change (%) 0.90%
Day's Open 14.31
Day's Range 14.19 - 14.65
Day's Volume 1,456,775
52-Week Range 2.20 - 17.14

More Stats

Market Cap 2.72B
Enterprise Value 2.56B
Earnings Date (est) Feb 4, 2021
Ex-Dividend Date n/a
Shares Outstanding 187.22M
Float 174.19M
EPS (basic) -0.28
EPS (diluted) -0.29
FCF / Share 0.09
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 0.53%
Payout Ratio n/a
Shares Short 14.99M
Short Ratio 3.05
Short % of Float 8.61%
Beta 1.06
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 188.09
PS Ratio 34.16
PB Ratio 21.80
Revenue 79.69M
Operating Income -98.33M
Net Income -45.62M
Free Cash Flow 14.47M
Net Cash 165.54M
Net Cash / Share 0.88
Gross Margin 43.39%
Operating Margin -123.39%
Profit Margin -57.30%
FCF Margin 18.16%
ROA -27.17%
ROE -50.55%
ROIC -40.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 2
Overweight 0
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$14.00*
(-3.71% downside)
Low
12.0
Current: $14.54
High
16.0
Target: 14.00
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue90.8978.6393.4790.7192.7860.5928.1825.9833.861.67
Revenue Growth15.6%-15.88%3.04%-2.23%53.12%115.02%8.46%-23.27%1922.88%-
Gross Profit34.5825.1034.6644.1653.4523.406.420.9413.031.67
Operating Income-101-101-89.78-71.24-29.13-62.85-77.54-94.34-110-140
Net Income-84.13-103-92.19-74.38-31.70-66.16-79.29-94.47-109-140
Shares Outstanding15313510689.1575.6170.4862.7855.7353.879.94
Earnings Per Share-0.55-0.76-0.87-0.83-0.42-0.94-1.26-1.69-2.03-14.10
Operating Cash Flow-78.31-66.43-67.52-67.93-47.89-51.47-29.83-76.82-103-122
Capital Expenditures-2.84-1.85-10.39-8.20-2.97-1.61-0.91-1.70-9.28-5.26
Free Cash Flow-81.15-68.28-77.91-76.13-50.86-53.08-30.74-78.53-112-127
Cash & Equivalents49.1010262.8771.9882.27101113101177284
Total Debt61.6714.6613.6416.1114.9513.9913.352.792.933.04
Net Cash / Debt-12.5787.7049.2455.8767.3287.3699.1897.79175281
Assets148170144138131124136130218306
Liabilities93.0756.2157.9853.2257.5769.4467.0120.3026.8525.88
Book Value54.9211486.1084.6773.5454.9569.18109191280
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Pacific Biosciences of California, Inc.
Country United States
Employees 404
CEO Christian O. Henry

Stock Information

Ticker Symbol PACB
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: PACB
IPO Date October 27, 2010

Description

Pacific Biosciences of California designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. The company also provides consumable products, including SMRT cells, as well as various reagent kits designed for specific workflow such as template preparation to convert DNA into SMRTbell double-stranded DNA library formats including molecular biology reagents, such as ligase, buffers and exonucleases. In addition, it provides binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprises reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences has collaboration with Asuragen to develop assays for carrier screening and other applications based on SMRT sequencing technology and AmplideX PCR chemistry; Invitae Corporation focuses on the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.